Dicks Sporting Goods Inc vs Heron Therapeutics Inc — how do they compare? Dicks Sporting Goods Inc trades at $202.7 (market cap $18.35B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: Dicks Sporting Goods Inc is far larger — about 298.5× Heron Therapeutics Inc's market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DKS | HRTX | |
|---|---|---|
Market Cap | $18.35B | $61.47M |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $1.49 |
52-Week Low | $187.78 | $0.32 |
Enterprise Value | $25.14B | $168.21M |
Dividend Yield | 2.44% | — |
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $202.66, down 5.34% on the day, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a 4.71% net income margin and 20.9% ROE, while analyst consensus remains strongly bullish with a $263.22 price target. Recent news highlights DKS as a value stock pick with accelerating sales growth, though the stock faces near-term technical pressure.
The outlook remains positive given strong analyst support and consistent earnings performance, but investors should monitor the bearish technical indicators and upcoming Q2 2026 earnings report on August 25th. Key risks include retail sector competition and potential margin pressure as revenue growth outpaces profit growth in 2026 projections.
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →